Pharmacyclics Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

Date: May 15, 2018
Pages: 50
US$ 499.00
Pharmacyclics Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
Publisher: BAC Reports
Report type: Strategic Report
Delivery: E-mail Delivery - PDF (on default),
Hard Copy Mail Delivery (+US$ 190.00)

Download PDF Leaflet

Pharmacyclics Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
Pharmacyclics Inc. Fundamental Company Report provides a complete overview of the company’s affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between Pharmacyclics Inc. and its competitors. This provides our Clients with a clear understanding of Pharmacyclics Inc. position in the Pharmaceuticals and Biotechnology Industry.

  • The report contains detailed information about Pharmacyclics Inc. that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
  • Another part of the report is a SWOT-analysis carried out for Pharmacyclics Inc.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company’s strengths, weaknesses, opportunities, and possible threats against it.
  • The Pharmacyclics Inc. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency. This sort of company's information will assist and strengthen your company’s decision-making processes.
  • In the part that describes Pharmacyclics Inc. competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company’s competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
  • Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Pharmacyclics Inc. business.

About Pharmacyclics Inc.

Pharmacyclics, Inc. operates as a clinical-stage biopharmaceutical company focusing on developing and commercializing small-molecule drugs for the treatment of immune mediated disease and cancer.


The company’s pharmaceutical agents are synthetic small molecules designed to target key biochemical pathways involved in human diseases with critical unmet needs. It has four proprietary drug candidates under clinical development and two drug candidates under preclinical development. This includes a histone deacetylase inhibitor (PCI-24781) about to enter a Phase II clinical trial; an inhibitor of Factor VIIa (PCI-27483); an inhibitor of Bruton's tyrosine kinase (Btk) (PCI-32765) in a Phase I clinical trial targeting oncology applications; a series of Btk inhibitors in advanced preclinical lead optimization and testing targeting autoimmune and allergic indications; and HDAC8 inhibitors (PCI-34051 and others) that are being optimized for autoimmune and cancer indications. Motexafin gadolinium (MGd) has completed accrual in two Phase II trials being conducted by the National Cancer Institute (NCI) in patients with newly diagnosed glioblastoma multiforme and pediatric pontine glioma.

Drug Development Programs

PCI-24781 (Pan HDAC Inhibitor): PCI-24781 is a potent, small-molecule inhibitor of HDAC enzymes with anti-tumor activity in vitro and in vivo. PCI-24781 treatment leads to synergistic efficacy in tumor cells in combination with DNA-damaging agents, such as radiation and chemotherapy agents. PCI-24781 has activity against primary human tumors from patients with colon, ovarian, lung, and hematological (blood related) cancers.

PCI-27483: PCI-27483 is a highly optimized and small molecule inhibitor of Factor VIIa developed by Pharmacyclics' scientists. This drug inhibits the active form of Factor VII (called Factor VIIa). PCI-27483 is a potent inhibitor of coagulation Factor VII.

Btk Inhibitors

The company develops orally bioavailable inhibitors of Bruton's tyrosine kinase (Btk), a signaling molecule that is critically important for the activity of B-cells (cells that lead to the productions of antibodies) and mast cell (a cell involved in allergic responses). Specific cancer indications include non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), and as a potential inhibitor of tumor stem cells (also known as Tumor Initiating Cells or TIC's) that have been identified in certain cancers. In addition, Btk inhibitors have potential for treatment of autoimmune diseases, such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and allergic diseases, such as urticaria, rhinitis, eosoniphilic esophagitis.

Pharmacyclics has developed two programs of proprietary and chemically distinct inhibitors, producing one candidate optimized for oncology (PCI-32765) and in a Phase I clinical trial; and a series of Btk inhibitor molecules being optimized for autoimmune and allergic indications for an anticipated IND.

PCI-32765 for Oncology

The company developed small-molecule inhibitors of Btk using a proprietary scaffold and demonstrated oral efficacy in preclinical models of lymphoma and spontaneous lymphoma in dogs. It initiated a trial of PCI-32765 in spontaneous canine lymphoma in companion animals.

The company developed multiple pharmacodynamic assays to monitor inhibition of B-cells and mast cells in peripheral blood, including a proprietary assay that can be used to monitor active-site occupancy of Btk by its inhibitors.

Motexafin Gadolinium (MGd)

MGd is a radiation and chemotherapy sensitizing agent with a mechanism of action. MGd is designed to accumulate selectively in cancer cells. The company is evaluating MGd in glioblastoma multiforme (GBM).

Collaboration and License Agreements

In April 2009, the company entered into a collaboration agreement with Les Laboratoires Servier pursuant to which Pharmacyclics granted to Servier a license for its Pan-HDAC inhibitors, including PCI-24781, for territories worldwide excluding the United States and its possessions. Under the terms of the agreement, Servier acquired the right to develop and commercialize the Pan-HDAC inhibitor product worldwide except for the United States and would pay a royalty to Pharmacyclics on sales outside of the United States.

Celera Genomics: In 2006, the company acquired multiple small molecule drug candidates for the treatment of cancer and other diseases from Celera Genomics, a Celera Corporation. Under the terms of the agreement, the company acquired Celera technology and intellectual property relating to drugs that target histone deacetylase (HDAC) enzymes, selective HDAC enzymes, a Factor VIIa inhibitor targeting a tumor signaling pathway involved in angiogenesis, tumor growth and metastases, and B-cell associated tyrosine kinase inhibitors potentially useful for the treatment of lymphomas and autoimmune diseases.

The University of Texas License: The company has a license agreement with the University of Texas under which the company received the exclusive worldwide rights to develop and commercialize porphyrins, expanded porphyrins and other porphyrin-like substances covered by their patents.


Pharmacyclics, Inc. was founded in 1991.

The above Company Fundamental Report is a half-ready report and contents are subject to change.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.




1.1. Key facts
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History


2.1. Business Description
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units


3.1. Overview
3.2. Strengths
3.3. Weaknesses
3.4. Opportunities
3.5. Threats


4.1. Financial Statements
  4.1.1. Income Statement
  4.1.2. Balance Sheet
  4.1.3. Cash Flow
4.2. Financial Ratios
  4.2.1. Profitability
  4.2.2. Margin Analysis
  4.2.3. Asset Turnover
  4.2.4. Credit Ratios
  4.2.5. Long-Term Solvency
  4.2.6. Growth Over Prior Year
  4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot


5.1. Pharmacyclics Inc. Direct Competitors
5.2. Comparison of Pharmacyclics Inc. and Direct Competitors Financial Ratios
5.3. Comparison of Pharmacyclics Inc. and Direct Competitors Stock Charts
5.4. Pharmacyclics Inc. Industry Analysis
  5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
  5.4.2. Pharmacyclics Inc. Industry Position Analysis


6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events


7.1. Experts Opinion
7.2. Experts Estimates



9.1. Political Factors
9.2. Economic Factors
9.3. Social Factors
9.4. Technological Factors
9.5. Environmental Factors
9.6. Legal Factors


10.1. Internal Factor Evaluation Matrix
10.2. External Factor Evaluation Matrix
10.3. Internal External Matrix





Pharmacyclics Inc. Key Facts
Management Effectiveness
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
Pharmacyclics Inc. Key Executives
Key Executives Biographies1
Key Executives Compensations1
Pharmacyclics Inc. Major Shareholders
Pharmacyclics Inc. History
Pharmacyclics Inc. Products
Revenues by Segment
Revenues by Region
Pharmacyclics Inc. Offices and Representations
Pharmacyclics Inc. SWOT Analysis
Yearly Income Statement Including Trends
Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
Pharmacyclics Inc. Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Credit Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
Pharmacyclics Inc. Capital Market Snapshot
Pharmacyclics Inc. Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Pharmaceuticals and Biotechnology Industry Statistics
Pharmacyclics Inc. Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
Pharmacyclics Inc. Consensus Recommendations1
Analyst Recommendation Summary1
Price Target Summary1
Experts Recommendation Trends1
Revenue Estimates Analysis1
Earnings Estimates Analysis1
Historical Surprises1
Revenue Estimates Trend1
Earnings Estimates Trend1
Revenue Revisions1


Pharmacyclics Inc. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Profit Margin Chart
Operating Margin Chart
Return on Equity (ROE) Chart
Return on Assets (ROA) Chart
Debt to Equity Chart
Current Ratio Chart
Pharmacyclics Inc. 1-year Stock Charts
Pharmacyclics Inc. 5-year Stock Charts
Pharmacyclics Inc. vs. Main Indexes 1-year Stock Chart
Pharmacyclics Inc. vs. Direct Competitors 1-year Stock Charts
Pharmacyclics Inc. Article Density Chart

1 – Data availability depends on company’s security policy.
2 – These sections are available only when you purchase a report with appropriate additional types of analyses.
The complete financial data is available for publicly traded companies.

SWOT Analysis

SWOT, which stands for Strengths, Weaknesses, Opportunities and Threats, is an analytical framework that identifies the internal and external factors that are favorable and unfavorable for a company.

Enhanced SWOT Analysis

Enhanced SWOT is a 3×3 grid that arranges strengths, weaknesses, opportunities and threats into one scheme:

  • How to use the strengths to take advantage of the opportunities?
  • How to use the strengths to reduce likelihood and impact of the threats?
  • How to overcome the weaknesses that obstruct taking advantage of the opportunities?
  • How to overcome the weaknesses that can make the threats a reality?

Upon answering these questions a company can develop a project plan to improve its business performance.

PESTEL Analysis

PESTEL (also termed as PESTLE) is an ideal tool to strategically analyze what influence different outside factors – political, economic, sociocultural, technological, environmental and legal – exert on a business to later chart its long term targets.

Being part of the external analysis when carrying out a strategic assessment or performing a market study, PESTEL gives an overview of diverse macro-environmental factors that any company should thoughtfully consider. By perceiving these outside environments, businesses can maximally benefit from the opportunities while minimizing the threats to the organization.

Key Factors Examined by PESTEL Analysis:

  • Political – What opportunities and pressures are brought by political bodies and what is the degree of public regulations’ impact on the business?
  • Economic – What economic policies, trends and structures are expected to affect the organization, what is this influence’s degree?
  • Sociological – What cultural and societal aspects will work upon the demand for the business’s products and operations?
  • Technological – What impact do the technological aspects, innovations, incentives and barriers have on the organization?
  • Environmental – What environmental and ecological facets, both locally and farther afield, are likely to predetermine the business?
  • Legal – What laws and legislation will exert influence on the style the business is carried out?

IFE, EFE, IE Matrices

The Internal Factor Evaluation matrix (IFE matrix) is a strategic management tool helping audit or evaluate major weaknesses and strengths in a business’s functional areas. In addition, IFE matrix serves as a basis for identifying and assessing relationships amongst those areas. The IFE matrix is utilised in strategy formulation.

The External Factor Evaluation matrix (EFE matrix) is a tool of strategic management that is typically utilised to assess current market conditions. It is an ideal instrument for visualising and prioritising the threats and opportunities a firm is facing.

The essential difference between the above mentioned matrices lies in the type of factors incorporated in the model; whilst the latter is engaged in internal factors, the former deals exceptionally with external factors – those exposed to social, political, economic, legal, etc. external forces.

Being a continuation of the EFE matrix and IFE matrix models, the Internal External matrix (IE matrix) rests upon an investigation of external and internal business factors integrated into one suggestive model.

Porter Five Forces Analysis

The Porter’s five forces analysis studies the industry of operation and helps the company find new sources of competitive advantage. The analysis surveys an industry through five major questions:

  1. What composes a threat of substitute products and services?
  2. Is there a threat of new competitors entering the market?
  3. What is the intensity of competitive rivalry?
  4. How big is the bargaining power of buyers?
  5. How significant is the bargaining power of suppliers?

VRIO Analysis

VRIO stands for Value, Rarity, Imitability, Organization. This analysis helps to evaluate all company’s resources and capabilities and bring them together into one aggregate table that includes:

  • Tangible resources
    • Financial
    • Physical
    • Technological
    • Organizational
  • Intangible resources
    • Human
    • Innovation and Creativity
    • Reputation
  • Organizational capabilities

The result of the analysis gives a clear picture of company’s competitive and economic implications, answering the questions if the resources mentioned above are:

  • Valuable?
  • Rare?
  • Costly to imitate?
  • Organized properly?
Skip to top

Apoptosis: Market Research Report US$ 4,200.00 Sep, 2011 · 617 pages

Ask Your Question

Pharmacyclics Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
Company name*:
Contact person*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: